All In Biotech

Drug Trial Radar · NCT07738679

Clinical Trial Evaluating the Efficacy and Safety of TQB3454 Tablets in Participants With Advanced Solid Tumors

Phase II Clinical Trial Evaluating the Efficacy and Safety of TQB3454 Tablets in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

127

Planned (sponsor's estimate)

Start

Jul 2026

Primary completion

Dec 2028

Study completion Sep 2029

Sponsor

Sponsor type
Industry
First posted
Jul 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter phase II study designed to evaluate the efficacy and safety of TQB3454 as monotherapy in patients with advanced solid tumors, divided into three cohorts.Cohort 1: Enrolled patients with diffuse glioma harbouring IDH1 R132 mutations. Cohort 2: Enrolled patients with advanced solid tumours (excluding glioma) harbouring IDH1 R132 mutations who failed standard therapy. Cohort 3: Enrolled patients with locally advanced, recurrent and/or metastatic biliary tract cancer without IDH1 mutations who progressed after gemcitabine or fluoropyrimidine-based treatment.

Conditions

  • Advanced Solid Tumors

Interventions

  • TQB3454 tabletsDrug

    TQB3454 is a selective inhibitor of the IDH1 mutant enzyme.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease Control Rate (DCR)Time frame: up to 48 weeks

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Sanbo Brain Hospital,Capital Medical University

    Beijing, Beijing Municipality, China

  • Xuanwu Hospital Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

  • The Second Hospital & Clinical Medical School, Lanzhou University

    Lanzhou, Gansu, China

  • Sun Yat-Sen Uuniversity Cancer Cerntr

    Guangzhou, Guangdong, China

  • AnYang Tumor Hospital

    Anyang, Henan, China

  • Luoyang Central Hospital (Zhengzhou University Affiliated Luoyang Central Hospital)

    Luoyang, Henan, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Zhengzhou University First Affiliated Hospital

    Zhengzhou, Henan, China

  • Jiangsu Provincial People's Hospital

    Nanjing, Jiangsu, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Liaoning Tumor Hospital & Institute

    Shenyang, Liaoning, China

  • The First Affiliated Hospital of Xi 'an Jiaotong University Medical College

    Xi'an, Shaanxi, China

  • Shandong Cancer Hosipital

    Jinan, Shandong, China

  • Shanghai Sixth People's Hospital, Shanghai Jiao Tong University

    Shanghai, Shanghai Municipality, China

  • The Second Affiliated Hospital of Air Force Medical University

    Xi’an, Shanxi, China

  • The Second Affiliated Hospital of Air Force Medical University

    Xi’an, Shanxi, China

  • SiChuan cancer hospital

    Chengdu, Sichuan, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.